Leaders in Pharmaceutical Business Intelligence (LPBI) Group

© 2016

“DrugDiscovery @LPBI Group”

is a Start Up in

Health/Life Sciences in MA

“DrugDiscovery @LPBI Group” combines expertise from three sources:

a.   Leadership of SBH Sciences, Inc, CEO, Raphael Nir, PhD

        Co-Founder: “DrugDiscovery @LPBI Group”, Expertise for Startup evolution:

• Management: Team building, Funding, Decision Making
• All Aspects of R&D Management
• Conceptual Leadership

b.   Leadership of LPBI Group, Founder, Aviva Lev-Ari, PhD, RN

       Co-Founder: “DrugDiscovery @LPBI Group”, Expertise for Startup evolution:

• Management: Team building, Funding, Administration
• R&D Management: Concept Design Strategy, Combination Drug Therapy

       Co-Founder “DrugDiscovery @LPBI Group”, Stephen J. Williams, PhD,                          Expertise for Startup evolution:

• Strategic Decision Making
• All Aspects of Research
• Conceptual Leadership in Drug Formulation
• 3D BioPrinting: Drug Dosing and Printing

c.   Team members of LPBI Group, M3DP Venture (Subsidiary #3)

c.1 Member of Technical Staff: Tilda Barliya, PhD, Expertise for Startup evolution:

• All Aspects of Research
• Conceptual Leadership in Drug Formulation, nano beads, oncology, genomics

c.2 Member of Technical Staff: Irina Robu, PhD, Expertise for Startup evolution:

• All Aspects of Research related to Material Science, Tissue Engineering
• Conceptual Leadership in Drug-Device design for drug delivery, Smart Polymers

c.3 Member of Technical Staff: David Orchard-Webb, Expertise for Startup evolution

• cancer biology, pancreatic disorders, biologics, molecular and cellular biology and immunology
• Conceptual Leadership in Novel mechanism of action and combination therapy of Biologics

We are adding Scientists to our Team

 

SBH Sciences, Inc. & LPBI Group’s M3DP, Subsidiary #3

Thrusts of  “DrugDiscovery @LPBI Group” include:

1. Drug Discovery with 3D BioPrinting
2. Drug Delivery System – One solution for many agents for many indications
3. Stem Cell Reprogramming & Gene Therapy
4. Gene Editing for Gene Therapies with 3D BioPrinting
5. JVIP – TEAM PRESENTATIONS 1/4/2016 – 3/31/2016

Drug Development – Three Indications

• Diabetes – A Combination Drug Therapy to induce Insulin Production by Pancreatic Beta Cells (PPAR-gamma, Leptin, ..)
• Inflammatory Disorders: Inflammatory Bowel Diseases (IBD) – Crohn’s and Ulcerative Colitis (UC) and Others
• Anti-Cancer Drug Discovery @ LPBI Group’s Research Biotech Businesses

Methodology and Processes

• CRISPR – genecards.org, UCSC, NM/OK, Caribou BioSciences
• PROTOCOL for LPBI Group’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered
• PROTOCOL for Drug Screening of 3rd Party Intellectual Property Presented for Funding Representation

The Team

Team Profile: DrugDiscovery @LPBI Group – A BioTech Start Up submitted for Funding Competition to MassChallenge Boston 2016 Accelerator

https://accelerate.masschallenge.org/startup/11021/team/

We are Applicants for MassChallenge Boston 2016 Accelerator

https://accelerate.masschallenge.org/startup/11021/team/

 

From: MassChallenge <apply@masschallenge.org>

Date: Monday, March 28, 2016 at 1:11 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: MassChallenge <apply@masschallenge.org>

Subject: Your MassChallenge 2016 Jun-Oct Program Cycle Application for DrugDiscovery@LPBI Group has been Submitted

Hi Aviva,

Thank you for submitting your application for MassChallenge Boston 2016 Accelerator for your startup, DrugDiscovery@LPBI Group. It has been received and will be reviewed by MassChallenge judges.

Best,

The MassChallenge Team

++

From: MassChallenge <contact@masschallenge.org>

Reply-To: <contact@masschallenge.org>

Date: Saturday, April 2, 2016 at 3:17 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: MC Update – Applications Close 

Boston, Jerusalem Lausanne – Timeline

February 9: Applications Open. Entrepreneurs apply online to MassChallenge 2016 programs.

March 2 (NOON EST): Early bird application deadline. Apply early and receive discounted application fee ($49).

April 1 (NOON EDT): Regular application deadline. This is the last date to submit applications for the 2016 accelerator programs. Regular application fee applies ($99).

March 29 – April 22: Round 1 Judging: Expert judges assess online applications and provide feedback to entrants. Each application receives scoring and feedback from multiple judges.  

May 4 – May 11: Round 2 Judging: Semi-finalist startups deliver 20-minute pitches to panels of judges in Boston, Lausanne, or Jerusalem. Live Q&A followed up by written scoring and feedback. 

May 19: Finalist Announcement. The most promising startups are invited to participate in the MassChallenge 2016 accelerator programs as finalists.

June 20 – October 14: Accelerator Program. Access to world-class mentorship, training, office space, funding, marketing, media and other resources. 

September 27 – September 29: Pre-final Judging: Finalists pitch to panels of judges highlighting their progress during the accelerator.

October 13 & 14: Final Judging. The top 26 startups pitch to high profile judges, who determine cash awards.

October 27: Israel Awards Ceremony. 

November 2: Boston Awards Ceremony. 

Click to Browse the 2016 Startup Applicants

About LPBI Group

Lines of Business #1,2,3,4,5 are in

• eScientific Digital Media & IP Asset Management (Subsidiary #1 and #4)

and in

• Funding Early Stage (Subsidiary #2)

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/ 

About “DrugDiscovery @LPBI Group”

“DrugDiscovery @LPBI Group” is assuming the activities of Subsidiary #5: SBH Sciences, Inc and LPBI Group’s Team in Biotech 3D BioPrinting R&D – Drug Development (Subsidiary #3: M3DP: Team in Drug Development and Team in Medical Devices)

• Subsidiary 3: Medical 3D BioPrinting – M3DP
• Subsidiary 5: Joint Ventures for IP Development – JVIP

We are in Research Biotech Businesses

• Subsidiary 3: R&D in 3D BioPrinting

Line-of-Business #6: “3D BioPrinting: Drugs” & “3DBioPrinting: Medical Devices”

Tissue Engineering, Gene Therapy: Stem Cells & Gene Editing, Medical Devices: Product Concepts

&

• Subsidiary 5: Pharmaceutical R&D: Drug Discovery and Drug-Devices Development

Line-of-Business #7:

• Drug Discovery with 3D BioPrinting

Line-of-Business #8:

• Drug Delivery System – One solution for many agents for many indications